[{"orgOrder":0,"company":"Bioblast Pharma Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Carbohydrate","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Bioblast Pharma Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioblast Pharma Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bioblast Pharma Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bioblast Pharma Ltd","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Carbohydrate","year":"2016","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bioblast Pharma Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioblast Pharma Ltd \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"Bioblast Pharma Ltd \/ Parexel"},{"orgOrder":0,"company":"Bioblast Pharma Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Trehalose API","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bioblast Pharma Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioblast Pharma Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bioblast Pharma Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bioblast Pharma Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Trehalose API","moa":"TFEB","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Bioblast Pharma Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioblast Pharma Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bioblast Pharma Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bioblast Pharma Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Tehalose","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Bioblast Pharma Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioblast Pharma Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bioblast Pharma Ltd \/ Undisclosed"}]